Immunotherapies in Lung Cancer, Part 2: Dr. Brahmer on Ipilumumab, Anti-PD1, Anticancer Viruses, and Talactoferrin

Howard (Jack) West, MD, Founder and President

Here's the second presentation from our program on "Immunotherapies for Lung Cancer: Can We Deliver on the Promise?".  Our first part was by Dr. Ramaswamy Govindan from Washington University in St. Louis; he was followed by Dr. Julie Brahmer, from Johns Hopkins University, who covered a wide range of immunotherapy concepts: the anti-CTLA4 antibody ipilimumab, or Yervoy; the exciting new approach of anti-PD1 therapy as was more fully presented at ASCO, new work on anticancer vaccine approaches, and discussion of talactoferrin and the past and ongoing trials with it.  

Below you'll find the audio and video versions of the podcast, along with transcript and figures.

Brahmer Immunotherapies for LC Part 2 Audio Podcast

Brahmer Immunotherapies for LC Part 2 Transcript

Brahmer Immunotherapies in LC Part 2 Figs

We'll close out this program with the question and answer session that followed the two presentations.  Look for that soon.

 

Video Language: 

Comments

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation